Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Phase 3 results reported through May 2026 show retatrutide produced mean weight loss of up to 28.3% at 80 weeks and 30.3% at 104 weeks in non-diabetic populations, with gastrointestinal adverse events the most common reported safety signal
30-40M American adults have used a GLP-1 medication for weight loss 2/3 of weight lost is regained within a year of stopping medication 40% of weight lost on GLP-1s can be muscle, not fat - without proper nutrition support Free resources to get started No signup required
The FTCs Gut Check also outlines what companies should not do
Who Might Be a Good Candidate for Each Type
The perspective that GLP-1s are a quick fix to obesity is in sharp contrast to the medical communitys recognition of obesity as a chronic disease, designated as such by the American Medical Association in 2013
All patients suspected of having an eating disorder should be referred to a specialist for a comprehensive assessment of eating disorder psychopathology before initiating obesity treatment
